
|Articles|October 1, 2009
Anti-VEGF monotherapy useful option in patients with RAP
Anti-VEGF monotherapy appears to be an effective treatment for retinal angiomatous proliferation, according to results of a small, retrospective chart review. Although the results indicate that in most cases repeated injections would be needed to achieve improvement of stable vision, treatment based on ocular coherence tomography-confirmed presence of fluid could achieve outcomes similar to monthly injections.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight
2
FLORetina 2025: New horizons in research and risk management for ROP
3
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage
4
FLORetina 2025: Port delivery system shows reliable 6-month durability and sustained efficacy in neovascular AMD for up to 7 years
5













































